

**IPHU Cape Town November 2019**

<b>Reports, chapters, open access articles and websites dealing with access to medicines (priority readings in green)</b>	
<b>GENERAL MATERIAL ON MEDICINES</b>	<b>TRIPS-PLUS</b>
<a href="#">GHW5, E3: People living with HIV in India: The Struggle for Access</a>	<a href="#">Smith S.R., Intellectual Property in Free Trade Agreements</a>
<a href="#">GHW4, D4: The TRIPS agreement: two decades of failed promises</a>	<a href="#">Impact of investment chapter provisions on access to medicines</a>
<a href="#">GHW4, D7: The ethical cost of offshoring clinical trials</a>	<a href="#">Memo: Ambiguity Leads to Fallacy: Biologics Exclusivity in the Trans-Pacific Partnership (final text)</a>
<a href="#">GHW3, D4: The Pharmaceutical Industry and Pharmaceutical Endeavour</a>	<a href="#">Correa, C. M. (2016). Innovation and the Global Expansion of Intellectual Property Rights: Unfulfilled Promises. Research Papers. Geneva, South Centre.</a>
<a href="#">GHW2, B5: Medicine</a>	<a href="#">United Nations Special Rapporteur on Right to Health's recommendations include: developing countries (and LDCs) should not agree to TRIPS+ and developed countries should not ask for TRIPS+</a>
<a href="#">GHW1, B2: Medicines</a>	<a href="#">UNITAID analysis of TPP IP chapter proposals that affect access to medicines (not final TPP text)</a>
<a href="#">WHO Commission on Intellectual Property Rights, Innovation and Public Health Report. <a href="http://www.who.int/intellectualproperty/report/en/">http://www.who.int/intellectualproperty/report/en/</a></a>	<a href="#">Impact on access to medicines</a>
<a href="#">WHO Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination. <a href="http://www.who.int/phi/CEWG_Report_5_April_2012.pdf?ua=1">http://www.who.int/phi/CEWG_Report_5_April_2012.pdf?ua=1</a></a>	<a href="#">Data exclusivity</a>
<a href="#">Jamie Love (2018) The savings from delinkage.</a>	<a href="#">Sengupta, A. (2018). Biological Drugs – Challenges to Access, Third World Network.</a>
<a href="#">Oxfam (2018) Prescription for poverty Drug companies as tax dodgers, price gougers, and influence peddlers</a>	<b><u>COUNTERFEIT, IP ENFORCEMENT &amp; ACCESS TO MEDICINES</u></b>
<a href="#">Drahos, P. and J. Braithwaite (2004). Who owns the knowledge economy? Political organizing behind TRIPS, Corner House Briefing (17 November), The Corner House.</a>	<a href="#">US Academic Exposes IP Maximalists' TRIPS plus plus Agenda. Third World Network</a>
<b><u>WHO DOCUMENTS</u></b>	<a href="#">Border Measures Concerning Goods Allegedly Infringing Intellectual Property Rights: The Seizure of Generic Medicines in Transit, Xavier Seuba</a>
<a href="#">WHO Global Strategy &amp; Plan of Action on Public Health, Innovation &amp; Intellectual Property</a>	
<a href="#">WHO Action Plan on Anti-microbial resistance.</a>	<a href="#">Shashikant, S. (2010). "The IMPACT counterfeit taskforce, intellectual property rights enforcement and seizure of medicines." TWN Intellectual Property Rights Series .</a>
<b><u>WTO DOCUMENTS &amp; DECISIONS</u></b>	<b><u>ANTIMICROBIAL RESISTANCE</u></b>

<a href="#">Doha Declaration on TRIPS and Public Health</a>	<a href="http://abrcoalition.com/">Declaration on Antibiotic Resistance http://abrcoalition.com/</a>
<a href="#">TRIPS Council Decision: General LDC Transition Period (IP/C/64)</a>	<a href="#">Lancet Infectious Diseases Commission (2013). "Antibiotic resistance-the need for global solutions."</a>
<a href="#">TRIPS Council Decision on LDC Pharmaceutical Transition Period until 2033 (IP/C/73)</a>	<a href="#">Jasovsky et al (2016). Antimicrobial Resistance - a threat to the World's Sustainable Development</a>
<a href="#">General Council Decision on Waivers for Exclusivity Marketing Rights &amp; Mailbox until 2033 for LDCs (WT/L/971)</a>	<a href="#">Antibiotic Resistance Coalition (2014). Act now, or face catastrophic post-antibiotic era</a>
<a href="#">2005 Decision Amending the TRIPS Agreement</a>	<a href="#">Alas, M. (2018). "State of discussion on AMR action, two years after the WHA Global Plan." South Bulletin 101</a>
<b>TRIPS FLEXIBILITIES</b>	<a href="#">Collignon et al (2018). "Anthropological and socioeconomic factors contributing to global antimicrobial resistance: a univariate and</a>
<a href="#">Exemption from pharmaceutical patents agreed for LDCs</a>	<a href="https://www.reactgroup.org/toolbox/">https://www.reactgroup.org/toolbox/</a>
<a href="#">Musungu and Oh, South Centre &amp; World Health Organization. The use of flexibilities in TRIPS by developing countries.</a>	<b>REGULATION</b>
<a href="#">Ling CY. Malaysia's experience in increasing access to antiretroviral drugs: exercising the "government use" option. Penang</a>	<a href="#">Berman (2012). The Role of Domestic Administrative Law in the Accountability of Transnational Regulatory Networks: The Case of the ICH</a>
<a href="#">TWN: Compulsory License and Government Use to Promote Access to Medicines: Some Examples</a>	<a href="#">Oxfam (2011). Eye on the Ball. Medicine regulation – not IP enforcement – can best deliver quality medicines</a>
<a href="#">United Nations. Report of the United Nations Secretary-General's High-Level Panel on Access to Medicines: Promoting Innovation and Access to Health Technologies. 2016</a>	<b>Websites</b>
<a href="#">UNDP. Using Competition Law To Promote Access To Health Technologies: A Guidebook for Low and Middle Income Countries. UNDP. New York: 2014</a>	<a href="#">TRIPS @ WTO</a>
<a href="#">Guidelines for the Examination of Patent Applications relating to Pharmaceuticals</a>	<a href="#">IP Watch (incl Health Policy Watch)</a>
<a href="#">Country experiences in using TRIPS safeguards: Part 1</a>	<a href="#">TWN</a>
<a href="#">Country experiences in using TRIPS safeguards: Part II</a>	<a href="#">Bilaterals.org</a>
<a href="#">Gopakumar, K., 2012. The compulsory license on sorafenib: A right step to ensure access to medicines</a>	<a href="#">South Centre</a>
<a href="#">Gopakumar, K., 2013. What should we learn from the Novartis judgment?</a>	<a href="#">MSF Access</a>

<a href="#">UNAIDS, WHO and UNDP (2011). Using TRIPS flexibilities to improve access to HIV treatment: policy brief.</a>	<a href="#">Accessibsa</a>
<a href="#">Esmail, L. and J. Kohler (2012). "The politics behind the implementation of the WTO Paragraph 6 Decision in Canada to increase global drug access." Globalization and Health 8(1): 7.</a>	<a href="https://www.patentoppositions.org/">https://www.patentoppositions.org/</a>
	<a href="http://www.medspal.org">www.medspal.org</a>
	<a href="http://www.who.int/topics/intellectual_property/en/">http://www.who.int/topics/intellectual_property/en/</a>